2009
Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial)
Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). The American Journal Of Cardiology 2009, 104: 151-157. PMID: 19576338, DOI: 10.1016/j.amjcard.2009.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanConceptsBeta blockersHeart failureMyocardial infarctionBaseline characteristicsAcute Myocardial Infarction trialAngiotensin receptor blocker valsartanCombination of valsartanNonfatal cardiovascular eventsAngiotensin receptor blockersBeta-blocker useMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsRisk of deathSignificant survival advantageCardiovascular eventsSystolic dysfunctionVentricular dysfunctionVentricular functionSurvival advantageLower riskPatientsMortality rateBlockersValsartan
2008
Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry)
Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, Van de Werf F, Solomon SD, Califf RM, Velazquez EJ. Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). The American Journal Of Cardiology 2008, 102: 1427-1432. PMID: 19026290, DOI: 10.1016/j.amjcard.2008.07.033.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedClinical Trials as TopicDeath, Sudden, CardiacDrug PrescriptionsFemaleHospital MortalityHumansIncidenceLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPractice Patterns, Physicians'RegistriesRetrospective StudiesRisk AssessmentRisk FactorsTachycardia, VentricularTime FactorsVentricular FibrillationConceptsSustained VT/ventricular fibrillationVT/ventricular fibrillationBeta-blocker therapyAcute myocardial infarctionHeart failureVentricular fibrillationBeta blockersVentricular tachycardiaMyocardial infarctionAcute beta-blocker therapyOral beta blockadeBeta-blocker useHospital mortality rateSustained ventricular arrhythmiasMultivariable logistic regressionSustained ventricular tachycardiaRelation of mortalityBeta blockadeHospital mortalityHospital deathKillip classificationBaseline characteristicsVentricular arrhythmiasEarly mortalityWorse outcomes